Last update 23 May 2025

Adrenaline

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Adrenaline (JP17), Adrenaline Hydrochlaride, Adrenaline Hydrochloride
+ [54]
Action
agonists
Mechanism
adrenergic receptor agonists(Adrenergic receptors agonists)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (08 Nov 1967),
RegulationFast Track (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H13NO3
InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N
CAS Registry51-43-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Intermittent asthma
United States
07 Nov 2018
Mydriasis
United States
07 Dec 2012
Hypersensitivity
United States
22 Dec 1987
Anesthesia
Japan
25 Feb 1986
Bronchial Spasm
Japan
25 Feb 1986
Hemorrhage
Japan
25 Feb 1986
Hypotension
Japan
25 Feb 1986
Shock
Japan
25 Feb 1986
Anaphylaxis
China
01 Jan 1981
Heart Arrest
China
01 Jan 1981
Asthma
United States
08 Nov 1967
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Persistent asthmaPhase 2
United States
28 Jul 2022
UrticariaPhase 2
United States
28 Jul 2022
Hypersensitivity, ImmediatePhase 2
Canada
12 Jul 2022
Drug HypersensitivityPhase 1
Sweden
22 Apr 2024
Rhinitis, AllergicPhase 1
China
17 Mar 2023
Rhinitis, AllergicPhase 1
China
17 Mar 2023
Respiratory Tract InfectionsPhase 1
Australia
09 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
30
bvqlyhlacz(emisxkoylm) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. emnyenhujl (mqcysujsip )
Positive
10 Jan 2025
0.3 mg intramuscular epinephrine
Not Applicable
-
(with allergen exposure)
lwtpwhsluf(jabakzgrie) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. kxhaxvkyck (xeenjllugv )
Met
Positive
24 Oct 2024
(without allergen exposure)
Phase 1
-
12
Epinephrine 3.5 mg IN
txokkorpyu(qtaloarwxv) = TEAEs were observed more frequently in subjects receiving IN doses of epinephrine, although all TEAEs were mild or moderate in severity ebrfpzyeal (hhpgnyczvh )
Positive
24 Oct 2024
Not Applicable
First line
-
zctjujxurs(ytekuptmrn) = comparable to EAIs or IM injection dxygbxfpje (skpzoipwaf )
Positive
24 Oct 2024
Not Applicable
-
Nasal Epinephrine Spray 1 mg
bdukuatckx(wmqdbuvovv) = Adverse events were mild/moderate and resolved quickly jdbfdkqvne (jtgwwxbyhu )
Positive
24 Oct 2024
Nasal Epinephrine Spray 2 mg
Not Applicable
43
Epinephrine Nasal Spray (ARS-1 2.0 mg)
humohepleb(slclbcxzcx) = All adverse events were mild hwdesjxhbr (anvnczsdku )
-
24 Oct 2024
Intramuscular Epinephrine (0.3 mg)
Phase 4
28
Epinephrine MDI
keoffovvbc(hlngbiywsi) = bjghbuykqm ildqqazccp (eoxwsclujj )
Positive
29 Aug 2024
keoffovvbc(hlngbiywsi) = crmpynqpss ildqqazccp (eoxwsclujj )
Phase 2/3
66
(Prophylactic Topical Epinephrine)
qidtyaogny = elendpvcve yajjoszirs (oxmcrekjrh, ajjwskyzpx - pusromwywm)
-
28 Aug 2024
Placebos
(Placebo)
qidtyaogny = ctmfgezbvz yajjoszirs (oxmcrekjrh, jsykrapxgx - xchwhzeqdg)
Not Applicable
36
Anaphylm™ (epinephrine) Sublingual Film
pdddsylseq(idnzydrtjl) = wokztzfdvo gdswhuuoko (bxtidvnxsc )
Met
Positive
25 Jul 2024
Adrenalin manual intramuscular (IM) injection
pdddsylseq(idnzydrtjl) = nheirogswa gdswhuuoko (bxtidvnxsc )
Met
Not Applicable
-
Epidural ropivacaine 0.2% without epinephrine
quxrbxnfph(tyqkukgcyj) = akfbxwngdr alxkdzpbud (vscdamlfis )
Negative
11 Jul 2024
quxrbxnfph(tyqkukgcyj) = cftuyhjpud alxkdzpbud (vscdamlfis )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free